Posted February 10, 2018 10:19:14 A new type of drugmaker has found a way to make a drug with a higher-quality formula, which is less toxic than its traditional counterparts.
A new type to be developed by the University of Manchester and drugmaker MDA Pharma is using bioengineered yeast to make more bioactive ingredients.
The company is working with bioengineers from the University, Imperial College London, to create an antibiotic that can be made by a combination of yeast and bacteria.
This makes it possible to make antibiotics without using traditional bacteria-based methods and it could be a game-changer for pharmaceutical manufacturing.
It could also allow pharmaceutical manufacturers to create a much cheaper and more effective antibiotic.
This could lead to new antibiotic-resistant bacteria that would then be more difficult to treat.
The new yeast-based compound can be used as an antibiotic in other ways.
The first step is to grow the yeast on a synthetic scaffold.
This will make it possible for the yeast to produce bioactive compounds such as peptides and peptidases.
They are important to make drugs that work on the body, but they also make a lot of other drugs that are used in other places.
Bioengineers are now trying to figure out how to make these bioactive materials from yeast.
The University’s Professor Stephen Jones said this could be used to make biodegradeable pharmaceuticals, which would be more durable.
He said:”We are hoping to be able to make an antibiotic which can be biodegraded from the yeast, which means it would be bioplastically stable.”
That would be very useful because in the future, it might be useful to make things like antibiotics that are resistant to drugs that have been made with bacteria.”MDA Pharma chief executive Ian Roberts said: “This is a hugely exciting opportunity.
“There are a lot more people working on biotechnology, and we are really excited about this opportunity to apply our knowledge of bioengineering to medicine.”